Literature DB >> 19138365

Experimental models of Peyronie's disease. Implications for new therapies.

Nestor F Gonzalez-Cadavid1, Jacob Rajfer.   

Abstract

INTRODUCTION: Despite its high prevalence and impact on the quality of life of patients, and that it is an excellent model for the study of fibrotic processes, Peyronie's disease (PD) is an orphan disease in biomedical research. The development of animal and cell culture models has advanced substantially the understanding of its molecular and cellular pathology and the proposal of new therapies. AIM: To review the literature pertaining to the use of these models for the study of PD.
METHODS: PubMed search conducted from the first report of an animal model for PD.
RESULTS: This model, based on the finding that transforming growth factor beta1 (TGF beta 1) is overexpressed in the PD plaque, consists on the injection of TGF beta 1 into the tunica albuginea of the rat. This leads to a PD-like plaque retaining many of the histological and biochemical features of human PD. Another rat model, based on the hypothesis that the PD plaque arises from trauma to the penis, causing fibrinogen extravasation that initiates as fibrin a fibrotic response, consists on injection of fibrin into the tunica. The cell culture model is based on the demonstration that myofibroblasts are abundant in the human PD plaque.
CONCLUSIONS: These models have: (i) clarified the role of microtrauma, myofibroblasts, and oxidative stress in plaque development; (ii) demonstrated that this tissue is under sustained turnover by fibrotic and antifibrotic mechanisms; (iii) showed the interplay of collagenolytic and fibrinolytic systems and their inhibitors; (iv) detected an endogenous antifibrotic process consisting of the expression of inducible nitric oxide synthase that counteracts oxidative stress, collagen synthesis, and myofibroblast generation; (v) characterized the antifibrotic effects of chronic treatment with phosphodiesterase type 5 (PDE5) inhibitors; (vi) discovered the cytogenetic instability of PD cells and alterations in their gene expression; and (vii) detected stem cells in the tunica albuginea with a potential role in fibrosis and ossification.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19138365     DOI: 10.1111/j.1743-6109.2008.01104.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  15 in total

1.  PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT.

Authors:  Aylin N Bilgutay; Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2015-06-01

Review 2.  Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Nat Rev Urol       Date:  2010-03-09       Impact factor: 14.432

3.  Sildenafil promotes smooth muscle preservation and ameliorates fibrosis through modulation of extracellular matrix and tissue growth factor gene expression after bilateral cavernosal nerve resection in the rat.

Authors:  Fara Sirad; Su Hlaing; Istvan Kovanecz; Jorge N Artaza; Leah A Garcia; Jacob Rajfer; Monica G Ferrini
Journal:  J Sex Med       Date:  2011-01-26       Impact factor: 3.802

4.  Sexual dysfunction: The potential of stem cell therapy for Peyronie disease.

Authors:  Alan W Shindel
Journal:  Nat Rev Urol       Date:  2012-11-20       Impact factor: 14.432

5.  Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix.

Authors:  Alan W Shindel; Guiting Lin; Hongxiu Ning; Lia Banie; Yun-Ching Huang; Gang Liu; Ching-Shwun Lin; Tom F Lue
Journal:  J Sex Med       Date:  2010-03-30       Impact factor: 3.802

6.  Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-β1 therapies in inducible nitric oxide synthase-deficient mice.

Authors:  Monica G Ferrini; Joanne Moon; Steve Rivera; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  BJU Int       Date:  2011-08-18       Impact factor: 5.588

7.  The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets.

Authors:  Robert A Gelfand; Dolores Vernet; Istvan Kovanecz; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  J Sex Med       Date:  2014-12-11       Impact factor: 3.802

8.  Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie's disease.

Authors:  Fabio Castiglione; Petter Hedlund; Frank Van der Aa; Trinity J Bivalacqua; Patrizio Rigatti; Hein Van Poppel; Francesco Montorsi; Dirk De Ridder; Maarten Albersen
Journal:  Eur Urol       Date:  2012-09-24       Impact factor: 20.096

9.  Effects of sildenafil treatment on patients with Peyronie's disease and erectile dysfunction.

Authors:  U Ozturk; S Yesil; H N G Goktug; A Gucuk; C Tuygun; N C Sener; I Nalbant; M A Imamoglu
Journal:  Ir J Med Sci       Date:  2013-11-05       Impact factor: 1.568

Review 10.  Molecular Mechanisms and Current Pharmacotherapy of Peyronie's Disease: A Review.

Authors:  Fuxun Zhang; Feng Qin; Jiuhong Yuan
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.